What are the key takeaways from this Biotech Hangout episode?

Key insights include: **China Competition Strategy:** US biotech maintains current leadership with 4,000 Chinese biotech companies emerging from 100 a decade ago. BIO advocates outcompeting rather than restricting China through regulatory modernization, faster clinical trial approvals, and reduced development costs. The approach focuses on strengthening the domestic innovation ecosystem rather than implementing restrictive policies that could backfire economically.; **FDA Workforce Crisis:** FDA operates with 20% fewer staff than 18 months ago, creating regulatory bottlenecks and inconsistency. The agency received hiring freeze exemption to add 1,000 scientific reviewers and inspectors, with 400 offers currently extended. Full staffing restoration and training will require 1-2 years, delaying improvements in review consistency and transparency across divisions like CBER and CDER.; **Clinical Trial Cost Reduction:** US clinical development costs create competitive disadvantage versus China. BIO works with FDA to streamline IND requirements, reduce contract negotiation timelines with academic centers, and implement AI for site selection and patient recruitment. Australia-style simplified approval processes serve as models for reducing barriers while maintaining safety standards and accelerating time to clinic.

What did John Crowley discuss on Biotech Hangout?

BIO CEO John Crowley discusses US-China biotech competition, FDA modernization challenges, vaccine hesitancy, and policy threats including MFN drug pricing and tariffs. The conversation covers regulatory reform needs, clinical trial cost reduction strategies, and industry efforts to maintain American innovation leadership while addressing access barriers and insurance reform priorities. Key topics include: **China Competition Strategy:** US biotech maintains current leadership with 4,000 Chinese biotech companies emerging from 100 a decade ago. BIO advocates outcompeting rather than restricting China through regulatory modernization, faster clinical trial approvals, and reduced development costs. The approach focuses on strengthening the domestic innovation ecosystem rather than implementing restrictive policies that could backfire economically.; **FDA Workforce Crisis:** FDA operates with 20% fewer staff than 18 months ago, creating regulatory bottlenecks and inconsistency. The agency received hiring freeze exemption to add 1,000 scientific reviewers and inspectors, with 400 offers currently extended. Full staffing restoration and training will require 1-2 years, delaying improvements in review consistency and transparency across divisions like CBER and CDER..

How long is this episode of Biotech Hangout?

This episode is 59 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Biotech Hangout

Episode 171 - January 30, 2026

January 30, 2026

59 min episode · 2 min read

John Crowley

Episode

59 min

Read time

2 min

Topics

Career Growth, Productivity, Fundraising & VC

AI-Generated Summary

Published Feb 12, 2026

Key Takeaways

✓China Competition Strategy: US biotech maintains current leadership with 4,000 Chinese biotech companies emerging from 100 a decade ago. BIO advocates outcompeting rather than restricting China through regulatory modernization, faster clinical trial approvals, and reduced development costs. The approach focuses on strengthening the domestic innovation ecosystem rather than implementing restrictive policies that could backfire economically.
✓FDA Workforce Crisis: FDA operates with 20% fewer staff than 18 months ago, creating regulatory bottlenecks and inconsistency. The agency received hiring freeze exemption to add 1,000 scientific reviewers and inspectors, with 400 offers currently extended. Full staffing restoration and training will require 1-2 years, delaying improvements in review consistency and transparency across divisions like CBER and CDER.
✓Clinical Trial Cost Reduction: US clinical development costs create competitive disadvantage versus China. BIO works with FDA to streamline IND requirements, reduce contract negotiation timelines with academic centers, and implement AI for site selection and patient recruitment. Australia-style simplified approval processes serve as models for reducing barriers while maintaining safety standards and accelerating time to clinic.
✓MFN Pricing Threat: Administration pushes to codify Most Favored Nation drug pricing into permanent law following 16 of 17 companies signing deals requiring MFN compliance and domestic manufacturing commitments. BIO argues implementation would be devastating and unmanageable, focusing congressional opposition on building firewalls while redirecting White House attention toward insurance reform and out-of-pocket cost caps instead.
✓New FDA Feedback Platform: BIO launches anonymous reporting system allowing companies to submit regulatory challenges ranging from complete response letters to individual reviewer issues. The platform synthesizes feedback monthly for FDA leadership review, elevating systemic problems to policy council level without requiring BIO access to confidential data. This creates structured recourse mechanism previously unavailable to smaller companies.

What It Covers

BIO CEO John Crowley discusses US-China biotech competition, FDA modernization challenges, vaccine hesitancy, and policy threats including MFN drug pricing and tariffs. The conversation covers regulatory reform needs, clinical trial cost reduction strategies, and industry efforts to maintain American innovation leadership while addressing access barriers and insurance reform priorities.

Key Questions Answered

•China Competition Strategy: US biotech maintains current leadership with 4,000 Chinese biotech companies emerging from 100 a decade ago. BIO advocates outcompeting rather than restricting China through regulatory modernization, faster clinical trial approvals, and reduced development costs. The approach focuses on strengthening the domestic innovation ecosystem rather than implementing restrictive policies that could backfire economically.
•FDA Workforce Crisis: FDA operates with 20% fewer staff than 18 months ago, creating regulatory bottlenecks and inconsistency. The agency received hiring freeze exemption to add 1,000 scientific reviewers and inspectors, with 400 offers currently extended. Full staffing restoration and training will require 1-2 years, delaying improvements in review consistency and transparency across divisions like CBER and CDER.
•Clinical Trial Cost Reduction: US clinical development costs create competitive disadvantage versus China. BIO works with FDA to streamline IND requirements, reduce contract negotiation timelines with academic centers, and implement AI for site selection and patient recruitment. Australia-style simplified approval processes serve as models for reducing barriers while maintaining safety standards and accelerating time to clinic.
•MFN Pricing Threat: Administration pushes to codify Most Favored Nation drug pricing into permanent law following 16 of 17 companies signing deals requiring MFN compliance and domestic manufacturing commitments. BIO argues implementation would be devastating and unmanageable, focusing congressional opposition on building firewalls while redirecting White House attention toward insurance reform and out-of-pocket cost caps instead.
•New FDA Feedback Platform: BIO launches anonymous reporting system allowing companies to submit regulatory challenges ranging from complete response letters to individual reviewer issues. The platform synthesizes feedback monthly for FDA leadership review, elevating systemic problems to policy council level without requiring BIO access to confidential data. This creates structured recourse mechanism previously unavailable to smaller companies.

Notable Moment

Crowley reveals the measles outbreak represents a critical inflection point where the administration's vaccine hesitancy tolerance may shift. Despite current advisory panel changes and vaccine compensation fund alterations, he expresses cautious optimism that escalating measles cases and potential loss of international vaccination status will force presidential intervention, as the president fundamentally opposes anti-vaccine positions despite political accommodation.

Know someone who'd find this useful?

Episode Transcript

You're listening to biotech hangout, a live and unedited weekly discussion of all the latest news in our industry with a group of biotech leaders and experts, and in my case, posers. I'm Josh Schumer. My cohost today are Sam Fazeli, Brian Skorney, Jeroen Werber. We are thrilled to also be joined by special guest John Crowley, president and CEO of BIO. For more information about our host and guest speakers or to listen to the most recent episode, please go to biotechhangout.com, where you'll also find our disclosures and, as always, noting that our commentary here should not be construed as investment advice since as today is proving, biotech investing is typically quite volatile and not for the faint of heart. Alright. Let's get right into it, John. Such a privilege to have you joining us today. What an important it's just an interesting time to get your perspectives on issues such as the biotech race with China, MFN, maybe even some of the ongoing challenges, at the FDA. Why why don't we start with your letter to the editor at the Wall Street Journal on the battle versus China and what, The US can be doing better to keep pace? Yeah. Great. Thank you. Thanks for having me. And and I think that letter and and maybe these opening comments on the competition vis a vis United States and China will help frame a number of the other issues because, you know, an important concept is every policymaker, every lawmaker we meet with, we start with why they need to care about biotech, And they need to care for three reasons. They need to care, as we all do, for the public health, you know, for our ability to make newer and better medicines, vaccines, therapeutics. Secondly, for biotech as an engine of economic growth. And third, for our national security, the notion that a strong, healthy, safe, prosperous workforce and population is vital to national security and ultimately to to everyone in the world. And also as an instrument of soft power for The United States and our allies. That resonates very well in the administration, Congress, bipartisan. I think we've made great inroads over the last year or so with getting everybody to understand what is biotech, why they need to care. And then of course, a lot of this is with the, you know, with respect to the competition with China. Our view there is that, you know, I think we're all familiar with the facts and figures of what's happening, the rise of Chinese biotech. When I first started going to China, with our manufacturing facility at Amicus there probably twelve, thirteen years ago, there were about a 100 or so we think Chinese bio true R and D Chinese biotech companies. Today with, you know, as we zero in on it, we think there are about at least 4,000. And And of course, you've all seen the number of medicines coming out of …

Get the full transcript (10,671 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Biotech Hangout transcripts →